Aprea Therapeutics Q2 EPS $(0.58) Beats $(0.64) Estimate, Sales $561.57K Beat $50.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Aprea Therapeutics (NASDAQ:APRE) reported Q2 earnings per share (EPS) of $(0.58), beating the analyst estimate of $(0.64) by 9.38%. The company also reported sales of $561.57K, surpassing the $50.00K estimate by 1,020%. This represents a significant improvement over the same period last year.
August 12, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aprea Therapeutics reported better-than-expected Q2 EPS of $(0.58) and sales of $561.57K, significantly beating analyst estimates. This marks a notable improvement from the previous year.
The company's better-than-expected EPS and sales figures indicate strong performance and potential investor confidence. The significant improvement over last year's figures further supports a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100